APO Research
Talk to an analyst

APO RESEARCH · REPORT

Malignant Ascites Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Malignant Ascites Treatment Market Analysis and Forecast 2026-2032

29 December 2025196 pages

Choose your research edition.

Industry ResearchMalignant Ascites Treatment Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Malignant Ascites Treatment Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Malignant Ascites Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Malignant Ascites Treatment Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Malignant Ascites Treatment Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Malignant Ascites Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Malignant Ascites Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Malignant Ascites Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Malignant Ascites Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Malignant Ascites Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Malignant Ascites Treatment include BD, Pfizer, B. Braun, The Surgical Company Group, Sequana Medical, PharmaCyte Biotech, Pfm Medical Ag, Merit Medical Systems and Medtronic, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Malignant Ascites Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Malignant Ascites Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Malignant Ascites Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Malignant Ascites Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Malignant Ascites Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Malignant Ascites Treatment revenue, projected growth trends, production technology, application and end-user industry.

Malignant Ascites Treatment Segment by Company

BD

Pfizer

B. Braun

The Surgical Company Group

Sequana Medical

PharmaCyte Biotech

Pfm Medical Ag

Merit Medical Systems

Medtronic

GI Supply (Laborie Medical Technologies)

CMP Pharma

Clover Biopharmaceuticals

BioVie

Malignant Ascites Treatment Segment by Type

Surgical Treatment

Chemotherapy

Paracentesis

Others

Malignant Ascites Treatment Segment by Application

Homecare

Hospitals

Clinics

Others

Malignant Ascites Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Malignant Ascites Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Malignant Ascites Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Malignant Ascites Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Malignant Ascites Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Malignant Ascites Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Malignant Ascites Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Malignant Ascites Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Surgical Treatment Major Player Table 3. Chemotherapy Major Player Table 4. Paracentesis Major Player Table 5. Others Major Player Table 6. Global Malignant Ascites Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Homecare Major Player Table 8. Hospitals Major Player Table 9. Clinics Major Player Table 10. Others Major Player Table 11. Malignant Ascites Treatment Industry Trends Table 12. Malignant Ascites Treatment Industry Drivers Table 13. Malignant Ascites Treatment Industry Opportunities and Challenges Table 14. Malignant Ascites Treatment Industry Restraints Table 15. Global Malignant Ascites Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Malignant Ascites Treatment Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Malignant Ascites Treatment Market Share by Region (2021-2026) Table 18. Global Malignant Ascites Treatment Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Malignant Ascites Treatment Market Share by Region (2027-2032) Table 20. Global Malignant Ascites Treatment Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Malignant Ascites Treatment Revenue Market Share by Players (2021-2026) Table 22. Global Malignant Ascites Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Malignant Ascites Treatment Key Players Headquarters & Area Served Table 24. Global Malignant Ascites Treatment Players, Product Type & Application Table 25. Global Malignant Ascites Treatment Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Malignant Ascites Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Malignant Ascites Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Malignant Ascites Treatment Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Malignant Ascites Treatment Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Malignant Ascites Treatment Revenue Market Share by Type (2021-2026) Table 32. Global Malignant Ascites Treatment Revenue Market Share by Type (2027-2032) Table 33. Global Malignant Ascites Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Malignant Ascites Treatment Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Malignant Ascites Treatment Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Malignant Ascites Treatment Revenue Market Share by Application (2021-2026) Table 37. Global Malignant Ascites Treatment Revenue Market Share by Application (2027-2032) Table 38. BD Company Information Table 39. BD Business Overview Table 40. BD Malignant Ascites Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. BD Malignant Ascites Treatment Product Portfolio Table 42. BD Recent Development Table 43. Pfizer Company Information Table 44. Pfizer Business Overview Table 45. Pfizer Malignant Ascites Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Pfizer Malignant Ascites Treatment Product Portfolio Table 47. Pfizer Recent Development Table 48. B. Braun Company Information Table 49. B. Braun Business Overview Table 50. B. Braun Malignant Ascites Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. B. Braun Malignant Ascites Treatment Product Portfolio Table 52. B. Braun Recent Development Table 53. The Surgical Company Group Company Information Table 54. The Surgical Company Group Business Overview Table 55. The Surgical Company Group Malignant Ascites Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. The Surgical Company Group Malignant Ascites Treatment Product Portfolio Table 57. The Surgical Company Group Recent Development Table 58. Sequana Medical Company Information Table 59. Sequana Medical Business Overview Table 60. Sequana Medical Malignant Ascites Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Sequana Medical Malignant Ascites Treatment Product Portfolio Table 62. Sequana Medical Recent Development Table 63. PharmaCyte Biotech Company Information Table 64. PharmaCyte Biotech Business Overview Table 65. PharmaCyte Biotech Malignant Ascites Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. PharmaCyte Biotech Malignant Ascites Treatment Product Portfolio Table 67. PharmaCyte Biotech Recent Development Table 68. Pfm Medical Ag Company Information Table 69. Pfm Medical Ag Business Overview Table 70. Pfm Medical Ag Malignant Ascites Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Pfm Medical Ag Malignant Ascites Treatment Product Portfolio Table 72. Pfm Medical Ag Recent Development Table 73. Merit Medical Systems Company Information Table 74. Merit Medical Systems Business Overview Table 75. Merit Medical Systems Malignant Ascites Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Merit Medical Systems Malignant Ascites Treatment Product Portfolio Table 77. Merit Medical Systems Recent Development Table 78. Medtronic Company Information Table 79. Medtronic Business Overview Table 80. Medtronic Malignant Ascites Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Medtronic Malignant Ascites Treatment Product Portfolio Table 82. Medtronic Recent Development Table 83. GI Supply (Laborie Medical Technologies) Company Information Table 84. GI Supply (Laborie Medical Technologies) Business Overview Table 85. GI Supply (Laborie Medical Technologies) Malignant Ascites Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. GI Supply (Laborie Medical Technologies) Malignant Ascites Treatment Product Portfolio Table 87. GI Supply (Laborie Medical Technologies) Recent Development Table 88. CMP Pharma Company Information Table 89. CMP Pharma Business Overview Table 90. CMP Pharma Malignant Ascites Treatment Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. CMP Pharma Malignant Ascites Treatment Product Portfolio Table 92. CMP Pharma Recent Development Table 93. Clover Biopharmaceuticals Company Information Table 94. Clover Biopharmaceuticals Business Overview Table 95. Clover Biopharmaceuticals Malignant Ascites Treatment Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Clover Biopharmaceuticals Malignant Ascites Treatment Product Portfolio Table 97. Clover Biopharmaceuticals Recent Development Table 98. BioVie Company Information Table 99. BioVie Business Overview Table 100. BioVie Malignant Ascites Treatment Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. BioVie Malignant Ascites Treatment Product Portfolio Table 102. BioVie Recent Development Table 103. North America Malignant Ascites Treatment Revenue by Type (2021-2026) & (US$ Million) Table 104. North America Malignant Ascites Treatment Revenue by Type (2027-2032) & (US$ Million) Table 105. North America Malignant Ascites Treatment Revenue by Application (2021-2026) & (US$ Million) Table 106. North America Malignant Ascites Treatment Revenue by Application (2027-2032) & (US$ Million) Table 107. North America Malignant Ascites Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. North America Malignant Ascites Treatment Revenue by Country (2021-2026) & (US$ Million) Table 109. North America Malignant Ascites Treatment Revenue by Country (US$ Million) & (2027-2032) Table 110. Europe Malignant Ascites Treatment Revenue by Type (2021-2026) & (US$ Million) Table 111. Europe Malignant Ascites Treatment Revenue by Type (2027-2032) & (US$ Million) Table 112. Europe Malignant Ascites Treatment Revenue by Application (2021-2026) & (US$ Million) Table 113. Europe Malignant Ascites Treatment Revenue by Application (2027-2032) & (US$ Million) Table 114. Europe Malignant Ascites Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. Europe Malignant Ascites Treatment Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe Malignant Ascites Treatment Revenue by Country (US$ Million) & (2027-2032) Table 117. China Malignant Ascites Treatment Revenue by Type (2021-2026) & (US$ Million) Table 118. China Malignant Ascites Treatment Revenue by Type (2027-2032) & (US$ Million) Table 119. China Malignant Ascites Treatment Revenue by Application (2021-2026) & (US$ Million) Table 120. China Malignant Ascites Treatment Revenue by Application (2027-2032) & (US$ Million) Table 121. Asia Malignant Ascites Treatment Revenue by Type (2021-2026) & (US$ Million) Table 122. Asia Malignant Ascites Treatment Revenue by Type (2027-2032) & (US$ Million) Table 123. Asia Malignant Ascites Treatment Revenue by Application (2021-2026) & (US$ Million) Table 124. Asia Malignant Ascites Treatment Revenue by Application (2027-2032) & (US$ Million) Table 125. Asia Malignant Ascites Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 126. Asia Malignant Ascites Treatment Revenue by Region (US$ Million) & (2021-2026) Table 127. Asia Malignant Ascites Treatment Revenue by Region (US$ Million) & (2027-2032) Table 128. SAMEA Malignant Ascites Treatment Revenue by Type (2021-2026) & (US$ Million) Table 129. SAMEA Malignant Ascites Treatment Revenue by Type (2027-2032) & (US$ Million) Table 130. SAMEA Malignant Ascites Treatment Revenue by Application (2021-2026) & (US$ Million) Table 131. SAMEA Malignant Ascites Treatment Revenue by Application (2027-2032) & (US$ Million) Table 132. SAMEA Malignant Ascites Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. SAMEA Malignant Ascites Treatment Revenue by Country (2021-2026) & (US$ Million) Table 134. SAMEA Malignant Ascites Treatment Revenue by Country (US$ Million) & (2027-2032) Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Malignant Ascites Treatment Image Figure 2. Global Malignant Ascites Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Malignant Ascites Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Surgical Treatment Image Figure 5. Chemotherapy Image Figure 6. Paracentesis Image Figure 7. Others Image Figure 8. Global Malignant Ascites Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Malignant Ascites Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 10. Homecare Image Figure 11. Hospitals Image Figure 12. Clinics Image Figure 13. Others Image Figure 14. Global Malignant Ascites Treatment Market Size (US$ Million) & (2021-2032) Figure 15. Global Malignant Ascites Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Malignant Ascites Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Malignant Ascites Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Malignant Ascites Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Malignant Ascites Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Malignant Ascites Treatment Revenue Market Share by Type (2021-2032) Figure 22. Global Malignant Ascites Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Malignant Ascites Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Malignant Ascites Treatment Revenue Market Share by Application (2021-2032) Figure 25. North America Malignant Ascites Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Malignant Ascites Treatment Revenue Share by Type (2021-2032) Figure 27. North America Malignant Ascites Treatment Revenue Share by Application (2021-2032) Figure 28. North America Malignant Ascites Treatment Revenue Share by Country (2021-2032) Figure 29. United States Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Malignant Ascites Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Malignant Ascites Treatment Revenue Share by Type (2021-2032) Figure 34. Europe Malignant Ascites Treatment Revenue Share by Application (2021-2032) Figure 35. Europe Malignant Ascites Treatment Revenue Share by Country (2021-2032) Figure 36. Germany Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Malignant Ascites Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Malignant Ascites Treatment Revenue Share by Type (2021-2032) Figure 46. China Malignant Ascites Treatment Revenue Share by Application (2021-2032) Figure 47. Asia Malignant Ascites Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Malignant Ascites Treatment Revenue Share by Type (2021-2032) Figure 49. Asia Malignant Ascites Treatment Revenue Share by Application (2021-2032) Figure 50. Asia Malignant Ascites Treatment Revenue Share by Region (2021-2032) Figure 51. Japan Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Malignant Ascites Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Malignant Ascites Treatment Revenue Share by Type (2021-2032) Figure 59. SAMEA Malignant Ascites Treatment Revenue Share by Application (2021-2032) Figure 60. SAMEA Malignant Ascites Treatment Revenue Share by Country (2021-2032) Figure 61. Brazil Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Malignant Ascites Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Surgical Treatment
  • Chemotherapy
  • Paracentesis
  • Others
Applications
  • Homecare
  • Hospitals
  • Clinics
  • Others
Companies covered
  • BD
  • Pfizer
  • B. Braun
  • The Surgical Company Group
  • Sequana Medical
  • PharmaCyte Biotech
  • Pfm Medical Ag
  • Merit Medical Systems
  • Medtronic
  • GI Supply (Laborie Medical Technologies)
  • CMP Pharma
  • Clover Biopharmaceuticals
  • BioVie

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Malignant Ascites Treatment Market by Type
  3. 1.2.1 Global Malignant Ascites Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Surgical Treatment
  5. 1.2.3 Chemotherapy
  6. 1.2.4 Paracentesis
  7. 1.2.5 Others
  8. 1.3 Malignant Ascites Treatment Market by Application
  9. 1.3.1 Global Malignant Ascites Treatment Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Homecare
  11. 1.3.3 Hospitals
  12. 1.3.4 Clinics
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Malignant Ascites Treatment Market Dynamics
  1. 2.1 Malignant Ascites Treatment Industry Trends
  2. 2.2 Malignant Ascites Treatment Industry Drivers
  3. 2.3 Malignant Ascites Treatment Industry Opportunities and Challenges
  4. 2.4 Malignant Ascites Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Malignant Ascites Treatment Market Perspective (2021-2032)
  2. 3.2 Global Malignant Ascites Treatment Growth Trends by Region
  3. 3.2.1 Global Malignant Ascites Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Malignant Ascites Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Malignant Ascites Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Malignant Ascites Treatment Revenue by Players
  2. 4.1.1 Global Malignant Ascites Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Malignant Ascites Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Malignant Ascites Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Malignant Ascites Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Malignant Ascites Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Malignant Ascites Treatment Players, Product Type & Application
  8. 4.5 Global Malignant Ascites Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Malignant Ascites Treatment Market CR5 and HHI
  11. 4.6.3 2025 Malignant Ascites Treatment Tier 1, Tier 2, and Tier 3
5 Malignant Ascites Treatment Market Size by Type
  1. 5.1 Global Malignant Ascites Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Malignant Ascites Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Malignant Ascites Treatment Revenue Market Share by Type (2021-2032)
6 Malignant Ascites Treatment Market Size by Application
  1. 6.1 Global Malignant Ascites Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Malignant Ascites Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Malignant Ascites Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 BD
  2. 7.1.1 BD Company Information
  3. 7.1.2 BD Business Overview
  4. 7.1.3 BD Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 BD Malignant Ascites Treatment Product Portfolio
  6. 7.1.5 BD Recent Developments
  7. 7.2 Pfizer
  8. 7.2.1 Pfizer Company Information
  9. 7.2.2 Pfizer Business Overview
  10. 7.2.3 Pfizer Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Malignant Ascites Treatment Product Portfolio
  12. 7.2.5 Pfizer Recent Developments
  13. 7.3 B. Braun
  14. 7.3.1 B. Braun Company Information
  15. 7.3.2 B. Braun Business Overview
  16. 7.3.3 B. Braun Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 B. Braun Malignant Ascites Treatment Product Portfolio
  18. 7.3.5 B. Braun Recent Developments
  19. 7.4 The Surgical Company Group
  20. 7.4.1 The Surgical Company Group Company Information
  21. 7.4.2 The Surgical Company Group Business Overview
  22. 7.4.3 The Surgical Company Group Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 The Surgical Company Group Malignant Ascites Treatment Product Portfolio
  24. 7.4.5 The Surgical Company Group Recent Developments
  25. 7.5 Sequana Medical
  26. 7.5.1 Sequana Medical Company Information
  27. 7.5.2 Sequana Medical Business Overview
  28. 7.5.3 Sequana Medical Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sequana Medical Malignant Ascites Treatment Product Portfolio
  30. 7.5.5 Sequana Medical Recent Developments
  31. 7.6 PharmaCyte Biotech
  32. 7.6.1 PharmaCyte Biotech Company Information
  33. 7.6.2 PharmaCyte Biotech Business Overview
  34. 7.6.3 PharmaCyte Biotech Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 PharmaCyte Biotech Malignant Ascites Treatment Product Portfolio
  36. 7.6.5 PharmaCyte Biotech Recent Developments
  37. 7.7 Pfm Medical Ag
  38. 7.7.1 Pfm Medical Ag Company Information
  39. 7.7.2 Pfm Medical Ag Business Overview
  40. 7.7.3 Pfm Medical Ag Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pfm Medical Ag Malignant Ascites Treatment Product Portfolio
  42. 7.7.5 Pfm Medical Ag Recent Developments
  43. 7.8 Merit Medical Systems
  44. 7.8.1 Merit Medical Systems Company Information
  45. 7.8.2 Merit Medical Systems Business Overview
  46. 7.8.3 Merit Medical Systems Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Merit Medical Systems Malignant Ascites Treatment Product Portfolio
  48. 7.8.5 Merit Medical Systems Recent Developments
  49. 7.9 Medtronic
  50. 7.9.1 Medtronic Company Information
  51. 7.9.2 Medtronic Business Overview
  52. 7.9.3 Medtronic Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Medtronic Malignant Ascites Treatment Product Portfolio
  54. 7.9.5 Medtronic Recent Developments
  55. 7.10 GI Supply (Laborie Medical Technologies)
  56. 7.10.1 GI Supply (Laborie Medical Technologies) Company Information
  57. 7.10.2 GI Supply (Laborie Medical Technologies) Business Overview
  58. 7.10.3 GI Supply (Laborie Medical Technologies) Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 GI Supply (Laborie Medical Technologies) Malignant Ascites Treatment Product Portfolio
  60. 7.10.5 GI Supply (Laborie Medical Technologies) Recent Developments
  61. 7.11 CMP Pharma
  62. 7.11.1 CMP Pharma Company Information
  63. 7.11.2 CMP Pharma Business Overview
  64. 7.11.3 CMP Pharma Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 CMP Pharma Malignant Ascites Treatment Product Portfolio
  66. 7.11.5 CMP Pharma Recent Developments
  67. 7.12 Clover Biopharmaceuticals
  68. 7.12.1 Clover Biopharmaceuticals Company Information
  69. 7.12.2 Clover Biopharmaceuticals Business Overview
  70. 7.12.3 Clover Biopharmaceuticals Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Clover Biopharmaceuticals Malignant Ascites Treatment Product Portfolio
  72. 7.12.5 Clover Biopharmaceuticals Recent Developments
  73. 7.13 BioVie
  74. 7.13.1 BioVie Company Information
  75. 7.13.2 BioVie Business Overview
  76. 7.13.3 BioVie Malignant Ascites Treatment Revenue and Gross Margin (2021-2026)
  77. 7.13.4 BioVie Malignant Ascites Treatment Product Portfolio
  78. 7.13.5 BioVie Recent Developments
8 North America
  1. 8.1 North America Malignant Ascites Treatment Revenue (2021-2032)
  2. 8.2 North America Malignant Ascites Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Malignant Ascites Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Malignant Ascites Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Malignant Ascites Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Malignant Ascites Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Malignant Ascites Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Malignant Ascites Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Malignant Ascites Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Malignant Ascites Treatment Revenue by Country
  11. 8.6.1 North America Malignant Ascites Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Malignant Ascites Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Malignant Ascites Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Malignant Ascites Treatment Revenue (2021-2032)
  2. 9.2 Europe Malignant Ascites Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Malignant Ascites Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Malignant Ascites Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Malignant Ascites Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Malignant Ascites Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Malignant Ascites Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Malignant Ascites Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Malignant Ascites Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Malignant Ascites Treatment Revenue by Country
  11. 9.6.1 Europe Malignant Ascites Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Malignant Ascites Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Malignant Ascites Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Malignant Ascites Treatment Revenue (2021-2032)
  2. 10.2 China Malignant Ascites Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Malignant Ascites Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Malignant Ascites Treatment Revenue by Type (2027-2032)
  5. 10.3 China Malignant Ascites Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Malignant Ascites Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Malignant Ascites Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Malignant Ascites Treatment Revenue by Application (2027-2032)
  9. 10.5 China Malignant Ascites Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Malignant Ascites Treatment Revenue (2021-2032)
  2. 11.2 Asia Malignant Ascites Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Malignant Ascites Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Malignant Ascites Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Malignant Ascites Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Malignant Ascites Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Malignant Ascites Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Malignant Ascites Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Malignant Ascites Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Malignant Ascites Treatment Revenue by Country
  11. 11.6.1 Asia Malignant Ascites Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Malignant Ascites Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Malignant Ascites Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Malignant Ascites Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Malignant Ascites Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Malignant Ascites Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Malignant Ascites Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Malignant Ascites Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Malignant Ascites Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Malignant Ascites Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Malignant Ascites Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Malignant Ascites Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Malignant Ascites Treatment Revenue by Country
  11. 12.6.1 SAMEA Malignant Ascites Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Malignant Ascites Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Malignant Ascites Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst